Skip to main content
Equibles

GLAXO · GlaxoSmithKline Pharmaceuticals Limited · Documents

Use GLAXO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GLAXO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
2,669.55 INR +14.25 (+0.54%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 4480 Avg daily vol (14 sessions) 12.12K

The company's reports, filings, earnings calls and investor events, most recent first. Search these from Claude or ChatGPT →

Earnings call Q2 2027 earnings call Held Nov 4, 2026
2026
Nov 4
Earnings call
Revenue rises 21% as Blenrep launch nears

GlaxoSmithKline Pharmaceuticals Limited reported Q2 revenue of INR1,180 crores, up 21%, and PAT growth of 33%. Management maintained its INR8,000 crores revenue aspiration by 2031 and planned the Blenrep launch in the December quarter.

6 source passages
From the management at GlaxoSmithKline Pharmaceuticals Limited, we have Mr. Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Limited; and Mr. Ronojit Biswas, Chief Financial Officer, GlaxoSmithKline Pharmaceuticals Limited. the results that were just announced for the Q2 of 2027 our, revenues during the September quarter increased 21% versus the previous year quarter to INR1,180 crores. Moving to PAT, profit after tax for the quarter grew 33%. the INR8,000 crores is an aspiration by 2031 We're very excited about, our launch of Blenrep, which is going to happen in the December quarter. Open the document at this passage
Showing 1–3 of 3 documents